Characterization of Pten and Trp53 deficient prostatic tumors in mice

Characterization of Pten and Trp53 deficient prostatic tumors in mice

Le cancer de la prostate est la forme de cancer la plus fréquente et la troisième cause de décès par cancer chez l’homme dans les sociétés occidentales. Alors que la plupart des cancers de la prostate localisés sont éradiqués chirurgicalement, la plupart des tumeurs métastatiques répondant initiale...

Full description

Bibliographic Details
Main Author:	El Bizri, Rana
Other Authors:	Strasbourg
Language:	en
Published:	2018
Subjects:	Cancer de la prostate Cellules épithéliales prostatiques Néoplasmes prostatiques intraépithéliaux Sénescence cellulaire Stress réplicatif Une réponse aux dommages de l’ADN Cancers de la prostate résistants à la castration Prostate cancer Prostatic epithelial cells Prostatic intraepithelial neoplasia Cell senescence Replication stress DNA damage response Castration-resistant prostate cancer 572.4 616.99
Online Access:	http://www.theses.fr/2018STRAJ097

Similar Items

Undesirable Status of Prostate Cancer Cells after Intensive Inhibition of AR Signaling: Post-AR Era of CRPC Treatment
by: Tomoyuki Makino, et al.
Published: (2021-04-01)

Prostate Cancer Stem Cells: Research Advances
by: Dagmara Jaworska, et al.
Published: (2015-11-01)

Androgen receptor and prostate cancer
by: Karen E. Livermore, et al.
Published: (2016-06-01)

Neuroendocrine and Aggressive-Variant Prostate Cancer
by: Nicholas Spetsieris, et al.
Published: (2020-12-01)

Role of chemotherapy in prostate cancer
by: Rita Nader, et al.
Published: (2018-01-01)

Drug treatment opportunities of the elderly patients with the metastatic castration-resistant prostate cancer
by: V. A. Solodkiy, et al.
Published: (2017-04-01)

Ureteral metastasis from locally invasive, castrate-resistant prostate cancer: a case report
by: Zachary C. Janatpour, et al.
Published: (2021-11-01)

Angiogenesis and Anti-Angiogenic Treatment in Prostate Cancer: Mechanisms of Action and Molecular Targets
by: Evangelia Ioannidou, et al.
Published: (2021-09-01)

POSSIBILITIES OF RADIUM-223 APPLICATION IN THERAPY OF PROSTATE GLAND CANCER
by: A. A. GRITSKEVICH, et al.
Published: (2017-06-01)

NCL Inhibition Exerts Antineoplastic Effects against Prostate Cancer Cells by Modulating Oncogenic MicroRNAs
by: Tyler Sheetz, et al.
Published: (2020-07-01)

Abiraterone Acetate Withdrawal Syndrome: Does It Exist
by: Hélène Gauthier, et al.
Published: (2012-07-01)

Development and prevalence of castration-resistant prostate cancer subtypes
by: Jordan E. Vellky, et al.
Published: (2020-11-01)

E74-like factor inhibition induces reacquisition of hormone sensitiveness decreasing period circadian protein homolog 1 expression in prostate cancer cells
by: Kohei Koyama, et al.
Published: (2015-03-01)

Metastatic castration-resistant prostate cancer in very elderly patients: challenges and solutions
by: Caffo O, et al.
Published: (2016-12-01)

Prostate radiation in non-metastatic castrate refractory prostate cancer provides an interesting insight into biology of prostate cancer
by: Pascoe Abigail C, et al.
Published: (2012-03-01)

Immunotherapy and Immune Evasion in Prostate Cancer
by: Archana Thakur, et al.
Published: (2013-05-01)

Predictors for progression of metastatic prostate cancer to castration-resistant prostate cancer in Indians
by: Sanjoy Kumar Sureka, et al.
Published: (2016-01-01)

Registered report: the androgen receptor induces a distinct transcriptional program in castration-resistant prostate cancer in man
by: Denise Chronscinski, et al.
Published: (2015-09-01)

Reciprocal deregulation of NKX3.1 and AURKA axis in castration-resistant prostate cancer and NEPC models
by: Moloud Aflaki Sooreshjani, et al.
Published: (2021-10-01)

Expression and ERG regulation of PIM kinases in prostate cancer
by: Sini K. Eerola, et al.
Published: (2021-05-01)

Validation of Cell-Free RNA and Circulating Tumor Cells for Molecular Marker Analysis in Metastatic Prostate Cancer
by: Michael Ladurner, et al.
Published: (2021-08-01)

Exceptional Response to Everolimus in a Patient with Metastatic Castrate-Resistant Prostate Cancer Harboring a PTEN Inactivating Mutation
by: Jamie A. Kmak, et al.
Published: (2020-04-01)

Optimal Sequencing and Predictive Biomarkers in Patients with Advanced Prostate Cancer
by: Carlo Cattrini, et al.
Published: (2021-09-01)

Prostatic Neoplasia in the Intact and Castrated Dog: How Dangerous is Castration?
by: Magdalena Schrank, et al.
Published: (2020-01-01)

Prostate Cancer Stem-like Cells Contribute to the Development of Castration-Resistant Prostate Cancer
by: Diane Ojo, et al.
Published: (2015-11-01)

Clinical outcome of surgical management for symptomatic metastatic spinal cord compression from prostate cancer
by: Yasuhide Miyoshi, et al.
Published: (2020-09-01)

Tumor lysis syndrome following cabazitaxel administration for metastatic castration‐resistant prostate cancer: A case report
by: Masashi Oshima, et al.
Published: (2019-07-01)

Hexane Insoluble Fraction from Purple Rice Extract Retards Carcinogenesis and Castration-Resistant Cancer Growth of Prostate Through Suppression of Androgen Receptor Mediated Cell Proliferation and Metabolism
by: Ranchana Yeewa, et al.
Published: (2020-02-01)

Estrogens and Their Receptors in Prostate Cancer: Therapeutic Implications
by: Erika Di Zazzo, et al.
Published: (2018-01-01)

Androgen Receptor Phosphorylation at Serine 308 and Serine 791 Predicts Enhanced Survival in Castrate Resistant Prostate Cancer Patients
by: Mark A. Underwood, et al.
Published: (2013-08-01)

miRNAs as Therapeutic Tools and Biomarkers for Prostate Cancer
by: Noemi Arrighetti, et al.
Published: (2021-03-01)

Clinical experience with abiraterone acetate application in patients with castration-resistant prostate cancer
by: Ya V Gridneva, et al.
Published: (2014-09-01)

Enzalutamide versus flutamide for castration-resistant prostate cancer after combined androgen blockade therapy with bicalutamide: study protocol for a multicenter randomized phase II trial (the OCUU-CRPC study)
by: Taro Iguchi, et al.
Published: (2019-04-01)

Clinical relevance of androgen receptor alterations in prostate cancer
by: Emma Jernberg, et al.
Published: (2017-10-01)

Weekly low-dose docetaxel is an effective treatment with fewer adverse events for metastatic castration-resistant prostate cancer in Taiwanese patients
by: Cheng-Li Kao, et al.
Published: (2015-12-01)

Prediction for survival following docetaxel-based chemotherapy in Taiwanese men with castration-resistant metastatic prostate cancer
by: Kai-Fu Yang, et al.
Published: (2015-12-01)

Real-world experience with abiraterone in metastatic castration-resistant prostate cancer
by: Yasar Ahmed, et al.
Published: (2017-01-01)

Retreatment with cabazitaxel in a long-surviving patient with castration-resistant prostate cancer and visceral metastasis
by: Raquel Luque Caro, et al.
Published: (2018-01-01)

Clinical implications of genomic evaluations for prostate cancer risk stratification, screening, and treatment: a narrative review
by: Jae-Seung Chung, et al.
Published: (2020-09-01)

Understanding prostate-specific antigen dynamics in monitoring metastatic castration-resistant prostate cancer: implications for clinical practice
by: Atsushi Mizokami, et al.
Published: (2017-01-01)

Cannot write session to /tmp/vufind_sessions/sess_ig5b1kb6t7nltl97i0k173id64